Microbiota-microglia crosstalk between Blautia producta and neuroinflammation of Parkinson's disease : A bench-to-bedside translational approach
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
Parkinson's disease (PD) is intricately linked to abnormal gut microbiota, yet the specific microbiota influencing clinical outcomes remain poorly understood. Our study identified a deficiency in the microbiota genus Blautia and a reduction in fecal short-chain fatty acid (SCFA) butyrate level in PD patients compared to healthy controls. The abundance of Blautia correlated with the clinical severity of PD. Supplementation with butyrate-producing bacterium B. producta demonstrated neuroprotective effects, attenuating neuroinflammation and dopaminergic neuronal death in mice, consequently ameliorating motor dysfunction. A pivotal inflammatory signaling pathway, the RAS-related pathway, modulated by butyrate, emerged as a key mechanism inhibiting microglial activation in PD. The change of RAS-NF-κB pathway in PD patients was observed. Furthermore, B. producta-derived butyrate demonstrated the inhibition of microglial activation in PD through regulation of the RAS-NF-κB pathway. These findings elucidate the causal relationship between specific gut microbiota and PD, presenting a novel microbiota-based treatment perspective for PD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
Brain, behavior, and immunity - 117(2024) vom: 05. März, Seite 270-282 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Jiaming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blautia producta |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 07.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbi.2024.01.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367021846 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367021846 | ||
| 003 | DE-627 | ||
| 005 | 20240308232325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbi.2024.01.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1320.xml |
| 035 | |a (DE-627)NLM367021846 | ||
| 035 | |a (NLM)38211635 | ||
| 035 | |a (PII)S0889-1591(24)00010-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Jiaming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Microbiota-microglia crosstalk between Blautia producta and neuroinflammation of Parkinson's disease |b A bench-to-bedside translational approach |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Parkinson's disease (PD) is intricately linked to abnormal gut microbiota, yet the specific microbiota influencing clinical outcomes remain poorly understood. Our study identified a deficiency in the microbiota genus Blautia and a reduction in fecal short-chain fatty acid (SCFA) butyrate level in PD patients compared to healthy controls. The abundance of Blautia correlated with the clinical severity of PD. Supplementation with butyrate-producing bacterium B. producta demonstrated neuroprotective effects, attenuating neuroinflammation and dopaminergic neuronal death in mice, consequently ameliorating motor dysfunction. A pivotal inflammatory signaling pathway, the RAS-related pathway, modulated by butyrate, emerged as a key mechanism inhibiting microglial activation in PD. The change of RAS-NF-κB pathway in PD patients was observed. Furthermore, B. producta-derived butyrate demonstrated the inhibition of microglial activation in PD through regulation of the RAS-NF-κB pathway. These findings elucidate the causal relationship between specific gut microbiota and PD, presenting a novel microbiota-based treatment perspective for PD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Blautia producta | |
| 650 | 4 | |a Gut-brain axis | |
| 650 | 4 | |a Neuroinflammation | |
| 650 | 4 | |a Parkinson's disease | |
| 650 | 4 | |a RAS-NF-κB signal pathway | |
| 650 | 4 | |a Short-chain fatty acids | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Butyrates |2 NLM | |
| 700 | 1 | |a Lv, Xinhuang |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhibo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Wenwen |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Huijia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Liuzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wen-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Kuan-Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain, behavior, and immunity |d 1992 |g 117(2024) vom: 05. März, Seite 270-282 |w (DE-627)NLM012962538 |x 1090-2139 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2024 |g day:05 |g month:03 |g pages:270-282 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbi.2024.01.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2024 |b 05 |c 03 |h 270-282 | ||